HCC or liver cancer is third most common cause of cancer related death worldwide. The 5-year survival rate of HCC is only 7percent. If detected earlier, surgical resection may result in improved prognosis as liver has the capability to regenerate itself. Presently, HCC is detected using Alpha-feto protein (AFP), which suffers from poor specificity and sensitivity in detecting HCC. We used proteomic and bioinformatic tools to identify putative biomarkers of HCC from both human tissue and plasma and then validated several of these using multiple-reaction-monitoring mass spectrometry.
展开▼
